17:06 IST
BSE
Business Update
Lupin Business Update
Lupin received US FDA approval for its Diazepam Injection, USP, enabling its commercialization in the U.S. market.
Lupin Ltd
Lupin Ltd news stories on ALFA NewsRead the news →- Share price
- ₹2,006.90
- Market cap
- ₹91,774 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 16.6×Sector 47.4×
- Promoter holding
- 46.85%-0.01% QoQ
- FII holding
- 22.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Regulatory Approval 10Other Announcement 9Employee Stock Options 7Earnings Call 5Product Launch 4Financial Results 4Merger & Restructuring 3Business Update 3Annual General Meeting 3Partnership 2Management Change 2Results Update 1Legal & Regulatory 1Dividend 1Board Meeting Outcome 1Board Meeting Date 1
Time
3 announcements with these filters
20:42 IST
BSE
Business Update
Lupin Business Update
Lupin Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's environmental, social, and governance performance.
21:53 IST
NSE
Business Update
Lupin Business Update
Lupin received an EIR from the U.S. FDA for its Somerset facility. The inspection resulted in a satisfactory VAI classification.